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Abstract
Background: CYP2C9 and VKORC1 are two major genetic factors associated with inter-individual variability in
warfarin dose. Additionally, genes in the warfarin metabolism pathway have also been associated with dose
variance. We analyzed Single Nucleotide Polymorphisms (SNPs) in these genes to identify genetic factors that
might confer warfarin sensitivity in Indonesian patients.
Methods: Direct sequencing method was used to identify SNPs in CYP2C9, VKORC1, CYP4F2, EPHX1, PROC and
GGCX genes in warfarin-treated patients. Multiple linear regressions were performed to model the relationship
warfarin daily dose requirement with genetic and non-genetic variables measured and used to develop a novel
algorithm for warfarin dosing.
Results: From the 40 SNPs analyzed, CYP2C9 rs17847036 and VKORC1 rs9923231 showed significant association
with warfarin sensitivity. In our study population, no significant correlation could be detected between CYP2C9*3,
CYP2C9C-65 (rs9332127), CYP4F2 rs2108622, GGCX rs12714145, EPHX1 rs4653436 and PROC rs1799809 with warfarin
sensitivity.
Conclusions: VKORC1 rs9923231 AA and CYP2C9 rs17847036 GG genotypes were associated with low dosage
requirements of most patients (2.05 ± 0.77 mg/day and 2.09 ± 0.70 mg/day, respectively). CYP2C9 and VKORC1
genetic variants as well as non-genetic factors such as age, body weight and body height account for 15.4% of
variance in warfarin dose among our study population. Additional analysis of this combination could allow for
personalized warfarin treatment in ethnic Indonesians.
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Background
Warfarin is the most widely used oral anticoagulant in
the world. It is usually prescribed for treatment of atrial
fibrillation, heart valve prosthesis, recurrent stroke, deep
vein thrombosis and pulmonary embolism [1]. Although
warfarin is indispensable for treatment of thromboem-
bolism and for prophylaxis of stroke, due to the large
inter-individual variation in the requirement for this
drug the appropriate dose to each patient is not easily
adjustable. An insufficient dose will result in failure to
prevent thrombosis, while overdose increases the risk of
unexpected bleeding. Pharmacogenetic differences are
believed to cause the variation in individual response to
warfarin [1,2].
Warfarin is primarily metabolized to the 7-hydroxy-
lated form in humans, principally by cytochrome P450
2C9. So far, more than 30 variant alleles in the CYP2C9
gene have been described (http://www.cypalleles.ki.se/
cyp2c9.htm). Two common allelic variants CYP2C9*2
(rs1799853) and CYP2C9*3 (rs1057910) are among the
most well characterized of the CYP2C9 alleles; both
alleles have been associated with reduced enzymatic
activity, and thus with reduced warfarin metabolism.
Individuals bearing variant alleles CYP2C9*2 and *3 are
reported to require a lower maintenance dose of war-
farin and a longer time to achieve stable dosing. These
individuals are also reported to have a higher proportion
of prothrombin-time measurements above therapeutic
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range, and to experience more frequent bleeding events
as compared to individuals with the CYP2C9*1 wild-
type allele [3].
Variability in warfarin response is also attributable to
variants in the vitamin K-related gene. Warfarin makes
use of its anticoagulant effects by interfering with regen-
eration of vitamin K by reduction of its 2,3-epoxide in
the vitamin K cycle, leading to inhibition of gamma-car-
boxylation of vitamin K-dependent clotting factor II
(prothrombin), VII, IX and X. Several reports have
demonstrated that non-coding SNPs in the vitamin K
related gene influenced warfarin sensitivity. These data
strongly suggest that differences in genetic variations in
both CYP and vitamin K-related genes could explain the
diversity in warfarin sensitivity and dose requirement
[2-4].
Many reports indicated an additive effect on warfarin
dose requirement in combinations of variant forms of
VKORC1 and CYP2C9 genes in Caucasian patients.
Furthermore, it is well known that there are significant
differences in warfarin dose requirement in different
ethnic groups; for example, Chinese patients were
reported to require a warfarin dose nearly 40% lower
than that required by Caucasian patients. The therapeu-
tic maintenance dose of warfarin for Japanese was also
31% lower than that for Caucasians [5].
Recent genome wide association studies have con-
firmed known polymorphisms in CYP2C9 and VKORC1
as the primary genetic determinants of stabilized war-
farin dose. Variants in both genes have been reported to
cause ~40% of the variability in warfarin dose. In addi-
tion SNP rs2108622 of CYP4F2 was reported to contri-
bute to 1%-2% of the variability [6,7].
In this study we investigate genetic variants previously
identified to associate with warfarin metabolism in other
populations, in order to identify genetic variations that
might confer sensitivity to warfarin in Indonesian
patients. Based on the gene variants, which are signifi-
cantly associated with warfarin sensitivity, we aim to
develop a prediction system that will be able to deter-
mine the dose appropriate to each patient in Indonesia.
Methods
Study population
All patients were unrelated ethnic Indonesians treated at
the National Cardiovascular Centre, Harapan Kita Hos-
pital, Jakarta, Indonesia for thromboembolic diseases,
such as atrial fibrillation, valve replacement, athero-
thrombotic diseases or congestive heart failure from
October 2007 to November 2008. All patients had a
stable dosage of warfarin for minimum 3 months and an
International Normalized Ratio (INR) of the Thrombo
Test within the range of 1.5-3.0. Patients with incom-
plete history of warfarin medication were excluded in
this study. Information about gender, age (missing in
two patients), bodyweight, body height (missing in two
patients), treatment indication and other diseases was
taken from the patients’ medical records. The ethical
committee of Harapan Kita Hospital, Jakarta, approved
the study. Prior to their participation in this study all
patients have given their written informed consents. For
genotyping purposes 122 subjects were included in this
study; of which 85 samples with complete medical infor-
mation were used in the statistical analysis for associa-
tion with warfarin dose requirement.
DNA isolation and genotyping
Genomic DNA was extracted from 200 μL whole blood
using Illustra Blood GenomicPrep Mini Spin Kit (GE
Healthcare, Buckinghamshire, UK) and QIAamp DNA
Blood Mini Kit (Qiagen, Hilden, Germany) according to
manufacturer’s standard protocol. The genomic DNA
concentration was measured using NanoDrop™ Spec-
trophotometer (Thermo Fisher Scientific, USA) and
adjusted to 10 ng/μl.
The initial screening of SNPs was performed using
122 samples for partial CYP2C9 locus, which included
Promoter regions, Exon 1, Exon 2, Exon 3, Exon 4,
Exon 5, Exon 6, Exon 7, Exon 8 and Exon 9. Genotyping
was also performed for VKORC1 (rs9923231); EPHX1
(rs4653436); GGCX (rs12714145); PROC (rs2069920;
rs1799808; rs1799809); and CYP4F2 (rs2108622). Pri-
mers used for CYP2C9 and VKORC1 genotyping were
designed according to Ref. [7,8]. The nucleotide position
for the primers were designed according to correspond-
ing published sequence in the NCBI database using Pri-
mer3 software (GenBank accession number NG_008385
for CYP2C9, NG_011564 for VKORC1, NG_011811.1
for GGCX, NG_009776 for EPHX1, M11228 for PROC
and NG_007971 for CYP4F2; Primer3 is available at
http://frodo.wi.mit.edu/primer3/).
The primer sequences were listed in Additional file 1:
Table S1. Approximately 30 ng of total DNA were sub-
jected to Polymerase Chain Reaction (PCR) amplifica-
tion in a final volume of 25 μL. Each PCR reaction
contained 1× PCR buffer (AmpliTaq® Gold, Applied
Biosystems, Foster City, CA), 1.5 mM MgCl2, 200 μM
dNTPs, 0.4 μM forward and reverse primers, and 0.625
U HotStart Taq Polymerase (Applied Biosystems, Foster
City, CA). The PCR were carried out in a Bio-Rad PTC-
200 DNA Engine Cycler with an initial denaturation
step of 10 min at 95°C, followed by 45 cycles of dena-
turation at 94°C for 30 s, annealing for 30 s (annealing
temperature of each primer were listed in Additional file
1: Table S1), and extension at 72°C for 1 min, with a
final extension for 10 min at 72°C. The purity and
mobility of each PCR product were confirmed in 2%
agarose gel electrophoresis; each PCR product was
Suriapranata et al. BMC Medical Genetics 2011, 12:80
http://www.biomedcentral.com/1471-2350/12/80
Page 2 of 9
either purified using Multi Screen PCR96 Filter Plate
(Millipore, Billerica, MA) or subjected to incubation
with 1 U of Shrimp Alkaline Phosphatase (New England
Biolabs, Ipswich, MA) and 1 U of Exonuclease I (New
England Biolabs, Ipswich, MA). Subsequently each PCR
product was sequenced using BigDye Terminator v3.1
Cycle Sequencing Kit and ABI Prism® 3130xl Genetic
Analyzer (Applied Biosystems, Foster City, CA) accord-
ing to manufacturer’s standard protocol. Each sample
was sequenced for both strands. All sequencing reac-
tions were performed at least twice with DNA amplified
from at least two independent PCR. Sequencing results
were aligned and analyzed for SNPs using BioEdit 7.0.0
program (Applied Biosystems, USA). All SNPs detected
in this study were located within the high quality region
of the chromatogram.
Statistical Analysis
Each polymorphism was tested for Hardy Weinberg
equilibrium in the study population. An adjustment for
multiple tests by Bonferroni correction was not applied
in our analysis. The Bonferroni correction is commonly
used by assuming that all tests are independent of each
other. However in practical applications, such as our
study; that is often not the case. The Bonferroni correc-
tion can be extremely conservative and leads to a high
rate of false negatives, which may also contribute to
publication bias [9]. Therefore Bonferroni correction in
which the P-values are multiplied by the number of
comparisons was not used in our analysis. Correlations
between warfarin dosage and clinical and genetic factors
were performed using the categoric Spearman-rank cor-
relation with 5% two-tailed significance level. Warfarin
dosage was log-transformed to normalize their distribu-
tion. Differences in the daily maintenance dose of war-
farin in the different genotype groups were calculated
using ANOVA with post hoc comparison using least
significant difference (LSD) analysis. Multiple linear
regressions were performed to model the relationship
warfarin daily dose requirement with other variables
measured and used to develop a novel algorithm for
warfarin dosing. P-value <0.05 was considered statisti-
cally significant. All statistical analyses were carried out
using SPSS 15 (SPSS Inc., Chicago, IL).
Results
This is a one-centre study on inter-individual variability
of warfarin dose requirements. Anticoagulant response is
measured by INR. Inclusion criteria were INR readings
between 1.5 and 3.0 during a minimum series of three
consecutive INR measurements for a period of 3 months.
The collected clinical data included gender, age, body-
weight, height and indication for anticoagulation. Clinical
characteristics of the patients were listed in Table 1.
We screened for polymorphisms in partial CYP2C9
locus including promoter region and regions surround-
ing exons 1 to 9, in addition to genetic variants in
VKORC1 (rs9393231) and CYP4F2 (rs2108622). Since
some reports have showed that genes other than
CYP2C9, VKORC1 and CYP4F2 might also contribute
to warfarin sensitivity, screening was also extended for
PROC promoter region and intron 3, EPHX1
(rs4653436), GGCX (rs1271415) [3,8,10]. A total of 40
SNPs were evaluated in our study; 22 SNPs with Minor
Allele Frequency (MAF) greater than 1% and their geno-
type distributions were listed in Table 2. The allele fre-
quencies were in the Hardy Weinberg Equilibrium
(HWE), except the polymorphism in GGCX rs12714145,
which was deviated from the HWE (P ≤ 0.05).
Two reported alleles for CYP2C9, CYP2C9*2 and *3
have been identified with decreased hydroxylation activ-
ity of the enzyme, which in turn can effect the efficacy
of anticoagulation [1,3]. Similar to earlier reports on
other Asian populations [7,8,10,11], CYP2C9*2 carriers
were not detected in our population (Table 2). We
searched for additional SNPs in CYP2C9 locus in the
promoter region of the gene, up to -700 bp upstream of
the transcriptional start site, and regions surrounding
exons 1 to 9. A total of 33 SNPs in CYP2C9 were geno-
typed in our study. Twelve known CYP2C9 allelic var-
iants were identified in our screen (CYP2C9*2 to
CYP2C9*13). CYP2C9*3 was detected with MAF greater
Table 1 Clinical characteristics of subjects





Male 58 ± 12 (26-78)
Female 56 ± 10 (32-71)
Bodyweight (kg)
Male 65.25 ± 10.41 (41-83)
Female 57.64 ± 14.27 (35-88)
Body height (cm)
Male 165.74 ± 6.74 (151-180)
Female 156.10 ± 5.06 (144-167)
Body Mass Index (kg/m2)
Male 23.93 ± 3.57 (15.72-36.52)
Female 23.46 ± 5.07 (15.55-32.55)
Indication for anticoagulation
Atrial fibrillation 24 (28.91%)
Heart valve replacement 13 (15.66%)
Atrial fibrillation and heart valve replacement 6 (7.23%)
Atherothrombotic diseases 8 (9.64%)
Other 32 (38.55%)
INR 2.11 ± 0.39 (1.48-3.00)
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Table 2 Allele frequencies and genotype distribution of SNPs evaluated in this study
Gene SNP Position relative to transcription start site Allele n % MAF Genotype n % P-Value HWE
CYP2C9** rs17847036 3259 G 265 98.15 0.9815 GG 130 96.30 0.8265
A 5 1.85 0.0185 GA 5 3.70
AA 0 0.00
Novel SNP 3164 G 224 91.80 0.9180 GG 102 83.61 0.3240
Intron 2 A 20 8.20 0.0820 GA 20 16.39
AA 0 0.00
rs9332120 3435 T 264 97.78 0.9778 TT 129 95.56 0.7917
C 6 2.22 0.0222 TC 6 4.44
CC 0 0.00
rs2860905 3880 G 224 91.80 0.9180 GG 104 85.25 0.1556
A 20 8.20 0.0820 GA 16 13.11
AA 2 1.64
rs28371675 3922 C 198 81.15 0.8115 CC 79 64.75 0.4291
T 46 18.85 0.1885 CT 40 32.79
TT 3 2.46
rs28371676 3948 T 234 95.90 0.9590 TT 112 91.80 0.6369
C 10 4.10 0.0410 TC 10 8.20
CC 0 0.00
rs28371677 4057 A 224 91.80 0.9180 AA 104 85.25 0.1556
G 20 8.20 0.0820 AG 16 13.11
GG 2 1.64
rs9332127 9056 G 234 95.90 0.9590 GG 112 91.80 0.6369
(CYP2C9C-65) C 10 4.10 0.0410 GC 10 8.20
CC 0 0.00
rs9332129 10322 A 234 96.69 0.9630 AA 112 92.56 0.6696
G 9 3.72 0.0370 AG 9 7.44
GG 0 0.00
rs1057910 42625 A 235 96.31 0.9631 AA 113 92.62 0.6723
(CYP2C9*3) C 9 3.69 0.0369 AC 9 7.38
CC 0 0.00
Novel SNP 47635 C 240 98.36 0.9836 CC 118 96.72 0.8539
Intron 8 T 4 1.64 0.0164 CT 4 3.28
TT 0 0.00
rs2298037 47650 C 199 81.56 0.8156 CC 79 64.75 0.1957
T 45 18.44 0.1844 CT 41 33.61
TT 2 1.64
rs9332238 50064 G 233 95.49 0.9549 GG 111 90.98 0.6020
A 11 4.51 0.0451 GA 11 9.02
AA 0 0.00
rs1934969 50067 A 173 70.90 0.7090 AA 60 49.18 0.5595
T 71 29.10 0.2910 AT 53 43.44
TT 9 7.38
rs1057911 50309 A 234 95.90 0.9590 AA 112 91.80 0.6369
T 10 4.10 0.0410 AT 10 8.20
TT 0 0.00
VKORC1 rs9923231 -1639 A 208 77.04 0.7704 AA 78 57.78 0.3027
G 62 22.96 0.2296 AG 52 38.52
GG 5 3.70
EPHX1 rs4653436 -2586 G 203 87.50 0.8750 GG 91 78.45 0.0633
A 29 12.50 0.1250 GA 21 18.10
AA 4 3.45
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than 1%, whereas CYP2C9*2 as well as CYP2C9*4 to
CYP2C9*13 were found to be homozygous in our study
population. The percentage frequencies for genotype
CYP2C9*1/*1 and CYP2C9*1/*3 were 92.62% and 7.38%
respectively (Table 2).
Additionally seven SNPs in CYP2C9, rs9332100 in
promoter region, rs12414460 and rs5031019 in exon 3,
rs9332173 in exon 6, rs1057909 in exon 7, rs17847032
in exon 8 and rs2017319 in exon 9, were identified as
homozygous SNPs in our population (data not shown).
Two novel CYP2C9 variants were detected in introns 1
and 8 with MAF of 8.2% and 1.64% respectively (Table
2). The two novel SNPs were detected in the position
3164 and 47635 relative to transcription start site.
Two SNPs in VKORC1, rs9934438 and rs9923231,
have been reported to correlate with pair-wise Linkage
Disequilibrium (LD) r2 values of 1.0 [7], therefore only
one SNP, rs9923231, was selected as candidate SNP in
our study. For rs9923231 or VKORC1 (-1639G > A)
allelic variation, 57.78% of our subjects were homozy-
gous for the wild-type A allele, 38.52% were heterozy-
gous and 3.7% were homozygous for the variant G allele.
Genetic variants in EPHX1 (rs4653436), GGCX
(rs12714145), PROC (rs2069920, rs1799808, rs1799809)
and CYP4F2 (rs2108622) were detected in our screen
with MAF of 12.50%, 40.57%, 42.62%, 40.57%, 22.53%
and 18.85% respectively (Table 2).
Together with non-genetic indicators such as gender,
age, body weight and height, all 22 identified SNPs with
MAF > 1% (Table 2) were evaluated as indicators for
warfarin dose association. The non-parametric Spear-
man-rank correlation of warfarin dose based on the
non-genetic and genetic factors is shown in Table 3.
Our results indicated that among the non-genetic
indicators included in the analysis, age and height were
significantly correlated with warfarin dose with a P-
value of 0.0232 and 0.0183 respectively. Bodyweight
exhibited a less significant association with daily war-
farin dose (P-value 0.0521). Among the 22 genetic indi-
cators analyzed, only rs17847036 in CYP2C9 and
rs9923231 in VKORC1 showed significant correlation
with warfarin dose with a P-value of 0.0058 and 0.0248
respectively (Table 3).
Comparisons of age, weight, height, maintenance INR
and warfarin dose were performed across the different
genotypes of CYP2C9 and VKORC1 using t-test. Patients
with GA genotype for CYP2C9 rs17847036 received sig-
nificantly higher doses of warfarin (3.67 ± 0.88 mg/day;
P-value 0.005) than patients with GG genotype (2.09 ±
0.70 mg/day). For VKORC1, patients carrying AA geno-
type for rs9923231 received lower dose albeit insignifi-
cantly (2.05 ± 0.77 mg/day; P-value 0.080) than patients
with AG or GG genotype (2.32 ± 0.73 mg/day).
The variability in warfarin stable dose for patients
grouped by the VKORC1 variants (AA, AG or GG for
Table 2 Allele frequencies and genotype distribution of SNPs evaluated in this study (Continued)
GGCX rs12714145 1291 C 145 59.43 0.5943 CC 34 27.87 0.0006
T 99 40.57 0.4057 CT 77 63.11
TT 11 9.02
PROC rs2069920 3643 C 140 57.38 0.5738 CC 36 29.51 0.1232
T 104 42.62 0.4262 CT 68 55.74
TT 18 14.75
PROC rs1799808 -141 C 99 40.57 0.4057 CC 15 12.30 0.0563
T 145 59.43 0.5943 CT 69 56.56
TT 38 31.15
PROC rs1799809 -128 A 141 57.79 0.7747 AA 72 59.02 0.3009
G 41 16.80 0.2253 AG 46 37.70
GG 4 3.28
CYP4F2 rs2108622 18454 C 198 81.15 0.8115 CC 82 67.21 0.3248
T 46 18.85 0.1885 CT 34 27.87
TT 6 4.92
** SNPs in CYP2C9 with MAF ≤ 0.01: CYP2C9*2 (rs1799853); CYP2C9*4 (rs56165452); CYP2C9*5 (rs28371686); rs17847032; rs2017319; CYP2C9*6 (rs9332131);
rs9332173; CYP2C9*7; CYP2C9*8 (rs7900194); rs5031019; CYP2C9*9 (rs2256871); CYP2C9*10 (rs9332130); CYP2C9*11 (rs28371685); rs1057909; CYP2C9*12
(rs9332239); rs9332100; CYP2C9*13; rs12414460.








Gender 0.1435 0.1900 85
Age -0.2490 0.0232 83
Bodyweight -0.2140 0.0521 83
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rs9923231) and CYP2C9 (AG or GG for rs17847036) is
shown in Figure 1. All patients were separated into four
categories according to the genotypes identified in
VKORC1 and CYP2C9. The median warfarin dose for
patients carrying heterozygous GA genotype for
CYP2C9 and AA genotype for VKORC1 was 3.33 mg/
day; higher than for patient group carrying homozygous
GG genotype for CYP2C9 and AA genotype for
VKORC1 with 2 mg/day (P-value 0.001).
Using the non-genetic and genetic indicators, we ana-
lyzed the effect of these indicators by multiple regres-
sion model analysis as shown in Table 4. The R2 value
varied depending on the indicators included in the five
different models used in our analysis. The model 5
showed the highest adjusted R2 value of 0.154; thus,
according to our analysis this model might be used to
explain 15.4% of the variance in the warfarin dose.
Figure 2 showed the correlation between warfarin dose
and the proposed model 5. Out of 85 patients included
in our analysis, our model could be used to predict the
dosage of 83 patients.
Discussion
Therapy with warfarin requires frequent monitoring due
to its narrow therapeutic index and inter-individual
variability in the dose necessary to reach a therapeutic
INR [1,12]. In this study we assessed the contribution of
previously reported genetic variants to inter-individual
variability in ethnic Indonesians [3,5-7,12,13]. This is the
first report on the effect of genetic polymorphisms on
warfarin dose requirement for this population. Based on
the analysis we conclude that age, body weight, body
height, and genetic variants of CYP2C9 and VKORC1
could explain for approximately 15.4% of the variability
in warfarin daily dose requirement of our study
population.
CYP2C9 metabolizes S-warfarin, the more active enan-
tiomer of warfarin, in the liver [14,15]. In our screen for
candidate SNPs in CYP2C9, we found that among the
known CYP2C9 variants identified, only CYP2C9*3 was
present in warfarin treated Indonesian patients. To some
extent this is in agreement with published reports from
other Asian populations including Chinese, Japanese,
Malaysian and Korean patients [10,16,17]. Nevertheless
other CYP2C9 genetic variants (e.g. CYP2C9*8, *11 and
*13) have been reported with minor allele frequencies
(MAF) as low as 1.02% in certain population [18-21].
Our analysis revealed that despite reports from other
populations [3,13,22-24], CYP2C9*3 was not significantly
associated with warfarin dose requirement in our study
(P-value 0.9308, data not shown). The probable reason
Figure 1 Box plot of the distribution for warfarin dose by
CYP2C9 rs17847036 (GG and GA) of CYP2C9 and VKORC1
rs9923231 (GG, AG and AA) genotypes. Number indicates the
median warfarin dose. P-values for the distributions in each
genotype are indicated.
Table 4 Multiple linear regression for estimation of
warfarin daily dose requirements based on age,
bodyweight, body height, CYP2C9 rs17847036 and
VKORC1 rs9923231




1 Age, Bodyweight and body height 0.094 0.059 0.053
2 CYP2C9 rs17847036 and VKORC1
rs9923231
0.106 0.084 0.010
3 Age, Bodyweight, body height and
CYP2C9 rs17847036
0.187 0.145 0.003
4 Age, Bodyweight, body height and
VKORC1 rs9923231
0.107 0.060 0.069
5 Age, Bodyweight, body height,
CYP2C9 rs17847036 and VKORC1
rs9923231
0.207 0.154 0.003
Figure 2 Correlation between warfarin dose and model 4
predicted value.
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for this might be the low number of subjects carrying a
single CYP2C9*3 allele and the absence of homozygous
CYP2C9*3 individuals in our study; further analysis with
a greater sample size will be required to confirm these
findings.
Our study suggested a genetic variant in the exon 2 of
CYP2C9, rs17847036, as a genetic factor that contribute
to warfarin sensitivity with a P-value of 0.005. Together
with non-genetic indicators such as patient age, body
weight and body height, this genetic variant could
explain about 14.5% of the inter-individual variability.
To the best of our knowledge this is the first time that
this polymorphism is linked with warfarin sensitivity. G/
A polymorphism in rs17847036 results in a synonymous
amino acid change in V76. Synonymous SNPs are not
expected to alter the function of the protein; however
the functional significance of these SNPs cannot be
overlooked. It has been reported that synonymous muta-
tions in coding regions may act alone or in combination
with other mutations in the same transcript to influence
mRNA stability and translation, thereby causing func-
tional effects [25]. Indeed, a “silent” polymorphism in
the Multi Drug Resistance (MDR1) gene has been attrib-
uted to alteration in the structure of substrate and inhi-
bitor interaction sites and thus to a change in substrate
specificity [26].
Recent genome-wide association studies for genetic
determinants of warfarin dose have verified the involve-
ment of CYP2C9*2 and *3 in warfarin sensitivity, and
additional genetic variants of CYP2C9 were not signifi-
cantly correlated with warfarin dose requirement [6,7].
Smaller studies however indicated that both genetic var-
iants might not be the major predictors for warfarin
dosing in African American population [27,28].
Recently, Scott et al. identified CYP2C9*8 genetic variant
as the most frequent variant in African Americans, and
suggested the incorporation of CYP2C9*8 into genotyp-
ing panels to improve dose prediction of CYP2C9-meta-
bolized drugs, including warfarin in this particular
ethnics [29]. It is therefore tempting to suggest, that
CYP2C9 variants other than CYP2C9*2 and *3 might be
associated with CYP2C9 enzymatic activity, and subse-
quently with warfarin dosing in different populations.
Nevertheless additional studies in larger populations are
required to confirm these findings.
Various publications have demonstrated the significant
role of VKORC1 -1639G/A polymorphism (rs9923231)
in warfarin requirements. Recent studies on VKORC1
suggested that SNPs in VKORC1 might contribute more
to dose variance than SNPs in CYP2C9 [3,11,15,23,29].
VKORC1 variants have been suggested to play a role on
transcriptional regulation and warfarin dose determina-
tion as haplotypes [30,31]. Indeed, Lee et al. reported
that individuals carrying VKORC1 H1 haplotype require
lower warfarin maintenance dose than individuals with
VKORC1 H7, H8 or H9 haplotypes [32]. Moreover,
these VKORC1 haplotypes were identified with variable
frequency in Chinese, Malayan and Indian populations.
Our result suggested that rs9923231 in VKORC1 con-
tributed less significantly than CYP2C9 genetic variant
rs17847036 (Table 4). From common VKORC1 variants
only rs9923231 was analyzed in this study, this SNP was
in LD with rs9934438 [13]. It is therefore conceivable
that other VKORC1 polymorphisms might additionally
contribute to dose variance in ethnic Indonesians; and
this warrants further investigation. Similar to other stu-
dies, our study also suggested that patients with AA
genotype in VKORC1 rs9923231 require lower doses of
warfarin than those with AG or GG genotype [11,33].
CYP4F2 genetic variant rs2108622 was associated with
a clinically relevant effect on warfarin requirement in
Caucasian populations [34,35]. This result was con-
firmed by a genome wide association study, which
reported that this CYP4F2 genetic variant might contri-
bute to 1%-2% of the variability in warfarin dose in Cau-
casian populations [7]. This genetic variant was detected
in our study population with a MAF of 18.85%; however
this polymorphism was not significantly correlated with
warfarin dose as indicated by a P-value of 0.9394 (data
not shown). In a UK study, CYP4F2 rs2108622 was not
associated with stable warfarin dose, but the authors
reported an association between CYP4F2 rs2189784 and
time-to-therapeutic INR, which confirmed the role of
CYP4F2 in vitamin K metabolism [36]. A functional reg-
ulatory CYP4F2 haplotype has also been associated with
increased susceptibility to hypertension and myocardial
infarction in Chinese and Japanese population, respec-
tively [37,38]. It is therefore tempting to suggest that
additional CYP4F2 variants or haplotypes might affect
warfarin dose requirement; and this needs further
clarifications.
Similarly, unique SNPs, such as rs9332127 (CYP2C9C-
65) and rs4653436 in EPHX1, were not strongly corre-
lated with warfarin dose. These SNPs were reported to
correlate with warfarin sensitivity in Chinese, Taiwanese
and Caucasian populations [3,13,24]. The observed P-
values for these genetic variants were 0.7304 and 0.6960
respectively (data not shown). Similar to Wang et al.
[13], we were not able to detect any correlation between
genetic variants in GGCX and PROC with warfarin dose
requirement, despite report on other populations [3,24].
This further confirms that polymorphisms in major war-
farin metabolizing genes might contribute not only to
inter-individual difference within a particular population
but also to inter-population variability among different
populations [24].
Taken together, the present study indicated that SNPs
in two major warfarin-metabolizing genes, CYP2C9 and
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VKORC1, contributed to the variability in warfarin dose
of ethnic Indonesians. This study demonstrated the
inter-individual variability in warfarin maintenance dose
was due to VKORC1 -1639G/A polymorphism
(rs9923231), CYP2C9 rs17847036, age, bodyweight and
height in Indonesian patients. Clinical factors such as
age, bodyweight and body height contributed to 5.9% of
warfarin reactivity. Interestingly, the two genetic factors,
VKORC1 -1639G/A polymorphism (rs9923231),
CYP2C9 rs17847036, were associated with a greater con-
tribution to warfarin sensitivity (8.4%). This clearly indi-
cated that genetic factors play an important role in
warfarin dosing in ethnic Indonesians similar to other
population. Analysis of the warfarin dosing algorithm by
multiple regression analysis showed that together with
the non-genetic factors, the genetic predictors accounted
for 15.4% of warfarin reactivity; thus this suggests that
additional genetic determinants might possibly contri-
bute to warfarin sensitivity in our study population.
Genetic variants in Apolipoprotein E (APOE), for exam-
ple, have been associated with warfarin metabolism.
Polymorphisms in APOE gene were found to influence
warfarin dose requirement differently in Caucasians,
African Americans and Asians [39,40]. Recent study also
identified a polymorphism in calumenin (CALU) (vita-
min K reductase regulator) as genetic factor for warfarin
requirement in African Americans [41]. Identification of
additional genetic variants and further evaluation of
common genetic predictors associated with warfarin
sensitivity might substantially improve warfarin dose
prediction for ethnic Indonesians.
Conclusions
The study confirmed that the impacts of genetic variants
on warfarin dosage requirement might vary in different
population. Together with non-genetic predictors the
genetic variants might be used to improve warfarin dose
prediction for ethnic Indonesians.
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